AI-generated analysis. Always verify with the original filing.
BioAge Labs, Inc. announced full year 2025 financial results with $9.0 million collaboration revenue, $73.9 million R&D expenses, $27.8 million G&A expenses, and $80.6 million net loss. Highlights include positive interim Phase 1 data for BGE-102 demonstrating 86% median hsCRP reduction and plans for Phase 2a trials, plus $132.3 million follow-on offering extending cash runway through 2029.
Event Type
Disclosure
Mandatory
Variant
8-K
, this Item 7.01, and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securiti
Regulation FD Disclosure The Company has also updated its corporate deck, which is available in the “Investors” portion of the Company’s website at https://ir.b
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by BioAge Labs, Inc. dated March 24, 2026. 104 Cover Page Inte
| Metric | Value | Basis |
|---|---|---|
| Collaboration Revenue | $9.00 | GAAP |
| Research and Development Expenses | $73.90 | GAAP |
| General and Administrative Expenses | $27.80 | GAAP |
| Net Loss | $80.60 | GAAP |
| Net Loss per Share, basic and diluted | $2.24 | GAAP |